1998
DOI: 10.1590/s0100-879x1998001200008
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Human subjects with active vulgar vitiligo do not respond well to autologous dermo-epidermal minigrafting. Eighteen subjects were treated with the α-melanocyte-stimulating hormone (α-MSH) synthetic analogue [Nle 4 , D-Phe 7 ]-α-MSH. The hormone (50 µl, 0.4 mM) was applied topically to 30-cm 2 lesions in which 29-48 minigrafts had been made. The hormone did not improve the success of the minigrafting and no differences were observed in local or distant repigmentation in treated subjects as compared to the place… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0
1

Year Published

2006
2006
2018
2018

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 32 publications
0
2
0
1
Order By: Relevance
“…Although this delivery form is not clinically useful, it does clearly demonstrate the ability for a synthetic α‐Msh analogue to provide photoprotection. While transdermal delivery works in mice, topical applications of synthetic α‐Msh to minigrafts on human vitiliginous skin appeared to have no effect on local or distant pigmentation despite successful recovery of functional synthetic hormone from urine 53 …”
Section: α‐Melanocyte Stimulating Hormone Agonists Forskolin and Cycmentioning
confidence: 99%
“…Although this delivery form is not clinically useful, it does clearly demonstrate the ability for a synthetic α‐Msh analogue to provide photoprotection. While transdermal delivery works in mice, topical applications of synthetic α‐Msh to minigrafts on human vitiliginous skin appeared to have no effect on local or distant pigmentation despite successful recovery of functional synthetic hormone from urine 53 …”
Section: α‐Melanocyte Stimulating Hormone Agonists Forskolin and Cycmentioning
confidence: 99%
“…Several isolated reports of therapy (123)(124)(125)(126)(127)(129)(130)(131)(132)(133)(134)(135)(136)(137)(138)(139)(140)(141)(142)(143)(144)(145)(146)(147)(148) …”
Section: Therapeutic Modalities Remarksunclassified
“…, thiambutosine(133), antimalarials(134), levodopa(135,136), UVA+mepacrine(137), lithium salts (138), Ginkgo biloba(139), Picrorhiza kurroa (140), pentoxyphyllin(141), topical mechlorethamine (142), intralesional tetracosactid (143), Efudix cream (144) (5% fluorouracil), Sicorten ointment (145), iontophoresis with 1% sodium salt of meladinine(146), topical melanotrophin(147), and di-hydroxyacetone(148).…”
mentioning
confidence: 99%